Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).
- Mechanism
- Curator reviewed
Anatibant is a new potent and selective non-peptide antagonist of the bradyknin B2 receptor. Anatibant crosses the blood brain barrier, reduces brain edema formation and brain damage, and improves neurological function following experimental traumatic brain injury. The underlying mechanisms are still not well understood. So far bradykinin B2 receptor-mediated neuroprotection was mainly explained by the reduction of vascular permeability and subsequent reduction of post-ischemic or post-traumatic brain edema.
- Primary indication
- Investigated for use/treatment in traumatic brain injuries.Curator reviewed
- Formula / weight
- C34H36Cl2N6O5S · 711.66 g/mol (avg)
- Code names
- LF16-0687MS
Resolves to
XUHBBTKJWIBQMY-MHZLTWQESA-NSMILESCC1=CC(C)=C2C=CC=C(OCC3=C(Cl)C=CC(=C3Cl)S(=O)(=O)N3CCC[C@H]3C(=O)NCCCNC(=O)C3=CC=C(C=C3)C(N)=N)C2=N1What you can answer from here — as of March 06, 2025
Which drugs share a target with Anatibant, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account